Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Merck, Pfizer combo treatment boosts kidney cancer survival

Merck & Co. Inc. said the combination of the drugmaker’s cancer immunotherapy Keytruda with Pfizer Inc.’s Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with the chemotherapy drug Sutent.

Read More »

Opdivo Plus Low-Dose Yervoy Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic RCC

Bristol-Myers Squibb Company announced new results from the Phase 3 CheckMate -214 study, showing that therapy with Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) continued to demonstrate long-term survival benefits in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).

Read More »

Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent

Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.

Read More »

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

The Japanese subsidiary of Pfizer Inc. is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in the active ingredient valsartan, the drugmaker said.

Read More »

Pfizer CEO Bourla plans to testify at Senate drug pricing hearing

U.S. drugmaker Pfizer Inc. said the company’s Chief Executive Albert Bourla plans to testify during February 2018 at a Senate hearing examining rising prescription drug prices.

Read More »

Trump says Americans pay too much for prescription drugs: speech excerpt

U.S. President Donald Trump said Americans are paying more than people in other countries for prescription drugs, according to excerpts from the State of the Union address.

Read More »

Roche adapts newer breast cancer drug in face of Herceptin imitations

Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.

Read More »

Powerful Senate committee invites pharma executives to testify

A powerful U.S. Senate committee invited seven pharmaceutical companies to testify at a hearing during February 2019 examining rising prescription drug prices.

Read More »

U.S. Senator Sanders asks why drug, once free, now costs $375k

U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals asking the company to justify the decision to charge $375,000 annually for a medication that for years has been available to patients for free.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom